A city-based lab is developing an immunotherapy drug for treating severely ill patients
Bangaluru: A city-based startup lab is developing an immunotherapy drug for treating severely ill patients, who have acute respiratory distress. This will be used to help late-stage Covid-19 patients who have acute respiratory distress and lung inflammation
Innaumation Medical Devices
Innaumation Medical Devices, which has been involved in various research and development activities to combat Covid-19, has been developing the immunotherapy drug. A team of six members comprising Dr Sachin Jadhav, Dr Ashish Doot, Dr Jyothsna Rao, Dr Gururaj Rao, Prof US Vishal Rao and Dr V Krupesh are involved in the development of the drug.
The team proposes to use mesenchymal cells to treat late stage patients who progress to acute respiratory distress and lung inflammation. Mesenchymal cells are known to possess anti-inflammatory, immuno-modulatory, and regenerative properties that can help alleviate symptoms of respiratory distress that are prevalent in late-stage Covid-19 patients.
”We propose the use of mesenchymal cells fro late-stage patients,” the team confirmed to BM, adding, “Patients who are on assisted-ventilation may be helped by using mesenchymal cells.” The US Food and Drug Administration had earlier this month approved the use of mesenchymal stem cell treatments in very ill Covid-19 patients.
Innaumation Medical Devices is among the six companies selected by the Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) to push forward Covid-19 innovations. Since the last week of March, C-CAMP has been inviting innovators, startups and entrepreneurs to push forward such innovations.
C-CAMP along with the United Nations Health Innovation Exchange (UNHIE) and Social Alpha had given a call on March 28 inviting innovators, startups and entrepreneurs with breakthrough innovations that are ready to deploy immediately or in the near future.